Loading…
ArriVent BioPharma, Inc. is projected to rise to $38.45 by 2027, a +29% move from its current price of $29.82. AVBP is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $28.98 | $29.83 | $30.70 | +0.03% |
| Aug 3 | $28.65 | $29.84 | $31.08 | +0.06% |
| Aug 4 | $28.39 | $29.85 | $31.38 | +0.10% |
| Aug 5 | $28.18 | $29.86 | $31.63 | +0.13% |
| Aug 6 | $28.00 | $29.87 | $31.86 | +0.16% |
| Aug 7 | $27.84 | $29.88 | $32.06 | +0.19% |
| Aug 8 | $27.69 | $29.89 | $32.26 | +0.22% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $27.69 | $29.89 | $32.26 | +0.22% |
| Week 2 | $26.89 | $29.95 | $33.36 | +0.44% |
| Week 3 | $26.30 | $30.02 | $34.26 | +0.67% |
| Week 4 | $25.83 | $30.09 | $35.04 | +0.89% |
| Week 5 | $25.42 | $30.15 | $35.76 | +1.12% |
| Week 6 | $25.07 | $30.22 | $36.43 | +1.34% |
| Week 7 | $24.75 | $30.29 | $37.06 | +1.57% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. Its lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd.
ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
ArriVent BioPharma, Inc. (AVBP) is currently priced at $30.44 with a market capitalization of $1.42B, and it ranks 2197. The current price sits in proximity to the 50-day simple moving average of $30.92, with the 200-day simple moving average at $24.97.
The forecast landscape projects sustained upside over time, with the 2026 average at $30.44 and meaningful growth thereafter, reaching $73.88 on average by 2030 and $466.21 on average by 2050, with corresponding max values to $111.04 in 2030 and $915.77 in 2050. The longer-horizon outlook also shows rising sentiment from Neutral in 2026 to Bullish in subsequent years, alongside substantial projected returns (ROI) of 0% in 2026, 28.1% in 2027, 33.1% in 2028, 74.4% in 2029, 142.7% in 2030, 169.7% in 2031, 206% in 2032, 229.9% in 2033, 249.1% in 2034, 300.9% in 2035, 605.5% in 2040, and 1431.6% in 2050.
A major floor 29.5% below — a decisive break under it would weaken the trend.
The nearest floor, 5.4% below — buyers have tended to step in here.
The nearest ceiling, 16.5% above — a clean break opens room to run.
A major ceiling 25.6% above — clearing it would confirm fresh momentum.
Key AVBP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AVBP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $30.13 | Sell | $30.25 | Sell |
| MA 10 | $30.09 | Sell | $30.62 | Sell |
| MA 20 | $31.77 | Sell | $31.21 | Sell |
| MA 50 | $31.27 | Sell | $30.95 | Sell |
| MA 100 | $29.03 | Buy | $29.24 | Buy |
| MA 200 | $25.32 | Buy | $26.79 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.58 | Neutral |
| Stoch RSI (14) | 49.43 | Neutral |
| CCI (20) | -77.16 | Neutral |
| Williams %R (14) | -67.81 | Info |
| MACD (12,26,9) | -0.26 | Sell |
| ROC (12) | -9.50 | Sell |
| Bollinger %B (20,2) | 0.24 | Neutral |
| Stochastic %K (14) | 32.19 | Neutral |
| TRIX (15) | -0.12 | Sell |
| Awesome (5,34) | -2.05 | Sell |
| Ultimate (7,14,28) | 41.22 | Neutral |
| Momentum (10) | -3.37 | Sell |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 30.04 | Sell |
| ADX (14) | 15.66 | Neutral |
| ATR (14) | 0.78 | Info |
The near-term technical picture shows bullish sentiment with RSI(14) at 40. The price is currently $30.44, sitting just under the 50-day SMA of $30.92, while the 200-day SMA sits at $24.97. Immediate support is identified at $28.22 and resistance at $34.74, suggesting a defined range in the near term.
The 30-day price range spans from $24.66 to $37.57, and annualized volatility stands at 60%, indicating elevated but manageable near-term risk.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $18.93 | $29.82 | $38.36 | 0% | Neutral | |
| $30.51 | $38.45 | $51.33 | +29% | Bullish | |
| $31.84 | $41.36 | $57.43 | +39% | Bullish | |
| $39.67 | $52.81 | $75.61 | +77% | Bullish | |
| $53.41 | $72.68 | $106.76 | +144% | Bullish | |
| $59.75 | $82.94 | $124.58 | +178% | Bullish | |
| $65.94 | $93.25 | $142.89 | +213% | Bullish | |
| $70.24 | $101.09 | $157.72 | +239% | Bullish | |
| $74.99 | $109.72 | $174.05 | +268% | Bullish | |
| $83.47 | $124.09 | $199.90 | +316% | Bullish | |
| $139.97 | $223.64 | $384.21 | +650% | Bullish | |
| $264.79 | $479.42 | $904.25 | +15.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $18.93 | $29.82 | $35.02 | +0.00% |
| September 2026 | $25.10 | $29.75 | $36.29 | -0.24% |
| October 2026 | $25.72 | $30.69 | $37.87 | +3.18% |
| November 2026 | $25.35 | $30.44 | $37.89 | -0.84% |
| December 2026 | $25.32 | $30.56 | $38.36 | +0.42% |
Click any year to see its month-by-month AVBP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The AVBP price prediction for 2026 points to an average of $29.82 (low $18.93, high $38.36) — a potential gain of 0% on today's $29.82. Price action looks broadly range-bound.
In 2027, AVBP is projected to trade between $30.51 and $51.33, averaging $38.45 — a potential gain of +29% from today's $29.82. That is up +29% on the projected 2026 average. Buyers look set to stay in control over this stretch.
ArriVent BioPharma, Inc.'s 2028 outlook centres on $41.36, within a $31.84 to $57.43 range. That is up +8% on the projected 2027 average. That marks a +39% change versus current levels. Momentum favours further upside here.
By 2029, AVBP could reach as high as $75.61, with a base case around $52.81 and support toward $39.67 — roughly +77% from $29.82. Buyers look set to stay in control over this stretch.
Expect AVBP to range from $53.41 to $106.76 through 2030. The $72.68 average target implies a +144% move from current prices. That is up +38% on the projected 2029 average. Momentum favours further upside here.
The AVBP price prediction for 2031 points to an average of $82.94 (low $59.75, high $124.58) — a potential gain of +178% on today's $29.82. Buyers look set to stay in control over this stretch.
In 2032, AVBP is projected to trade between $65.94 and $142.89, averaging $93.25 — a potential gain of +213% from today's $29.82. That is up +12% on the projected 2031 average. Momentum favours further upside here.
ArriVent BioPharma, Inc.'s 2033 outlook centres on $101.09, within a $70.24 to $157.72 range. That is up +8% on the projected 2032 average. That marks a +239% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, AVBP could reach as high as $174.05, with a base case around $109.72 and support toward $74.99 — roughly +268% from $29.82. Momentum favours further upside here.
Expect AVBP to range from $83.47 to $199.90 through 2035. The $124.09 average target implies a +316% move from current prices. That is up +13% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The AVBP price prediction for 2040 points to an average of $223.64 (low $139.97, high $384.21) — a potential gain of +650% on today's $29.82. Momentum favours further upside here.
In 2050, AVBP is projected to trade between $264.79 and $904.25, averaging $479.42 — a potential gain of +15.1x from today's $29.82. That is up +114% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in AVBP today (≈ 33.534541 AVBP) could be worth
$16,077.21
+$15,077.21 (+1508%) by 2050 · US Dollar
Based on the average projected AVBP price of $479.42 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AVBPwould be worth at today's price.
$1,000 invested in AVBP on Jul 31, 2025 (≈ 51.255766 AVBP) would be worth
$1,528.45
+$528.45 (+52.8%) today · 1.53× · US Dollar
Based on a AVBP entry price of $19.51 vs. today's $29.82.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $31.73 | $939.8 | -6.0% |
| 1 month ago | $34.5 | $864.35 | -13.6% |
| 3 months ago | $29.99 | $994.33 | -0.6% |
| 6 months ago | $22.67 | $1,315.39 | +31.5% |
| 1 year ago | $19.51 | $1,528.45 | +52.8% |
| All time (2.5y) ago | $20 | $1,491 | +49.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AVBP forecast.
Our base-case forecast reaches $60.00 around 2030.
Implied market cap at $60.00: $2.79B
Looking further out, the year-by-year forecast shows upside potential across multiple horizons. In 2026, the average price is $30.44 with a neutral sentiment and a 0% ROI, reflecting a baseline starting point. By 2027, the average climbs to $39.00 with bullish sentiment and a 28.1% ROI, followed by 2028 at $40.52 (28.4% implied) with bullish sentiment and a 33.1% ROI.
The trajectory continues higher, with 2030’s average at $73.88 and a max of $111.04, delivering a 142.7% ROI and bullish sentiment. In the 2040 forecast, the average rises to $214.75 with a max of $381.88 and a 605.5% ROI, still labeled bullish. By 2050, the average is projected to $466.21 with a max of $915.77 and a remarkable 1431.6% ROI, maintaining bullish sentiment.
These are estimates and not guarantees, reflecting a long-run-facing upside path with significant variability inherent in future outcomes.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $73.88, a min of $53.19, and a max of $111.04, with a 142.7% ROI and bullish sentiment.
The projected path shows substantial upside, with 2027 average $39.00, 2030 average $73.88, and 2050 max $915.77, delivering up to 1431.6% ROI. These are estimates and not guarantees, and risks remain.
Yes—the forecast for 2033 shows an average of $100.43 with a max of $161.07 and a 229.9% ROI, supported by bullish sentiment.
The 2050 forecast shows a max of $915.77, which does not reach $1,000 under the provided projections.
The current price is $30.44.
ArriVent BioPharma, Inc. Community Discussion
0Share your ArriVent BioPharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.